Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug–drug interaction
Millie Das(VA Palo Alto Health Care System), Heather A. Wakelee(Palo Alto Institute), Sukhmani K. Padda(Stanford University), Joel W. Neal(Stanford Medicine), Adam Frymoyer(University of California, San Francisco), Jonathan W. Riess(University of California Davis Medical Center), Lisa Zhou(Stanford University)
Cited by 25
Related Papers
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|805